211 related articles for article (PubMed ID: 22020193)
1. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.
Demicco EG; Torres KE; Ghadimi MP; Colombo C; Bolshakov S; Hoffman A; Peng T; Bovée JV; Wang WL; Lev D; Lazar AJ
Mod Pathol; 2012 Feb; 25(2):212-21. PubMed ID: 22020193
[TBL] [Abstract][Full Text] [Related]
2. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
3. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.
Sozopoulos E; Litsiou H; Voutsinas G; Mitsiades N; Anagnostakis N; Tseva T; Patsouris E; Tseleni-Balafouta S
Endocr Pathol; 2010 Jun; 21(2):90-100. PubMed ID: 20186503
[TBL] [Abstract][Full Text] [Related]
4. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
[No Abstract] [Full Text] [Related]
5. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
[TBL] [Abstract][Full Text] [Related]
6. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R
JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
8. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
[TBL] [Abstract][Full Text] [Related]
9. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Stemke-Hale K; Gonzalez-Angulo AM; Lluch A; Neve RM; Kuo WL; Davies M; Carey M; Hu Z; Guan Y; Sahin A; Symmans WF; Pusztai L; Nolden LK; Horlings H; Berns K; Hung MC; van de Vijver MJ; Valero V; Gray JW; Bernards R; Mills GB; Hennessy BT
Cancer Res; 2008 Aug; 68(15):6084-91. PubMed ID: 18676830
[TBL] [Abstract][Full Text] [Related]
10. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Catasus L; Gallardo A; Cuatrecasas M; Prat J
Mod Pathol; 2009 Apr; 22(4):522-9. PubMed ID: 19234438
[TBL] [Abstract][Full Text] [Related]
11. Myxoid pleomorphic liposarcoma is distinguished from other liposarcomas by widespread loss of heterozygosity and significantly worse overall survival: a genomic and clinicopathologic study.
Dermawan JK; Hwang S; Wexler L; Tap WD; Singer S; Vanderbilt CM; Antonescu CR
Mod Pathol; 2022 Nov; 35(11):1644-1655. PubMed ID: 35672466
[TBL] [Abstract][Full Text] [Related]
12. Active TGF-β signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart.
Verbeke SL; Bertoni F; Bacchini P; Oosting J; Sciot R; Krenács T; Bovée JV
Mod Pathol; 2013 Sep; 26(9):1211-21. PubMed ID: 23599148
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma.
Trautmann M; Cyra M; Isfort I; Jeiler B; Krüger A; Grünewald I; Steinestel K; Altvater B; Rossig C; Hafner S; Simmet T; Becker J; Åman P; Wardelmann E; Huss S; Hartmann W
Mol Cancer Ther; 2019 Apr; 18(4):834-844. PubMed ID: 30787173
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
[TBL] [Abstract][Full Text] [Related]
15. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
16. Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays.
Cheng H; Dodge J; Mehl E; Liu S; Poulin N; van de Rijn M; Nielsen TO
Hum Pathol; 2009 Sep; 40(9):1244-51. PubMed ID: 19368956
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA alterations in Middle Eastern ovarian cancers.
Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
[TBL] [Abstract][Full Text] [Related]
18. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
[TBL] [Abstract][Full Text] [Related]
19. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic PI3K and its role in cancer.
Samuels Y; Ericson K
Curr Opin Oncol; 2006 Jan; 18(1):77-82. PubMed ID: 16357568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
